Statins in Patients with COVID-19: A Retrospective Cohort Study in Iranian COVID-19 Patients

Payam Peymani
Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran

Tania Dehesh
Department of Biostatistics and Epidemiology, School of Public Health, Kerman University of Medical Sciences, Kerman, Iran

Farnaz Aligolighasemabadi
Department of Internal Medicine, Mashhad Medical Sciences Branch, Islamic Azad University, Mashhad, Iran

Mohammadamin Sadeghdoust
Department of Internal Medicine, Mashhad Medical Sciences Branch, Islamic Azad University, Mashhad, Iran

Katarzyna Kotis
Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland

Mazaher Ahmadi
Department of Analytical Chemistry, Faculty of Chemistry, Bu-Ali Sina University, Hamedan, Iran

Parvaneh Mehrbod
Influenza and Respiratory Viruses Department, Pasteur Institute of IRAN, Tehran, Iran

Pooya Iranpour
Medical Imaging Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Sanaz Dastghaib
Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Ahmad Nasimian
Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Amir Ravandi
Section of Cardiology, St. Boniface Hospital, University of Manitoba, Winnipeg, MB, Canada

Biniam Kidane
Department of Surgery, University of Manitoba, Manitoba, Canada

Naseer Ahmed
Department of Radiology, University of Manitoba, Canada

Pawan Sharma
Center for Translational Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Shahla Shojaei  
College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada

Kamran Bagheri Lankarani  
Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran

Andrzej Madej  
Faculty of Medicine, Katowice School of Technology, 40-555 Katowice, Poland

Nima Rezaei  
Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

Tayyebeh Madrakian  
Department of Analytical Chemistry, Faculty of Chemistry, Bu-Ali Sina University, Hamedan, Iran

Marek Los  
Biotechnology Center, Silesian University of Technology, 44-100 Gliwice, Poland

Hagar Ibrahim Labouta  
College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada

Pooneh Mokarram  
Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Saeid Ghavami (✉️ saeid.ghavami@gmail.com)  
University of Manitoba  https://orcid.org/0000-0001-5948-508X

Research

**Keywords:** COVID-19, SARS-CoV-2, Statins, Repurposing, Pleiotropic effects, Retrospective study

**DOI:** https://doi.org/10.21203/rs.3.rs-106030/v1

**License:** © This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

**Background:** The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has profoundly affected the lives of millions of people. To date, there is no approved vaccine or specific drug to prevent or treat COVID-19, while the infection is spreading at an alarming rate globally. Because the development of effective vaccines or novel drugs could take several months (if not years), repurposing existing drugs is considered a more efficient strategy that could save lives now. Statins constitute a class of lipid-lowering drugs with proven safety profiles and many known beneficial pleiotropic effects. Our previous investigations showed that statins have antiviral effects and are involved in the process of wound healing in the lung. This triggered us to evaluate if statin use reduces mortality in COVID-19 patients.

**Results:** After initial recruitment of 459 patients with COVID-19 (Shiraz province, Iran) and careful consideration of the exclusion criteria, a total of 150 patients, of which 75 received statins, were included in our retrospective study. Cox proportional-hazards regression models were used to estimate the association between statin use and rate of death. After propensity score matching, we found that statin use appeared to be associated with a lower risk of morbidity \( \text{HR} = 0.85, 95\% \text{ CI} = (0.02, 3.93), P = 0.762 \) and lower risk of death \( \text{HR} = 0.76; 95\% \text{ CI} = (0.16, 3.72), P = 0.735 \); however, these associations did not reach statistical significance. Furthermore, statin use reduced the chance of being subjected to mechanical ventilation \( \text{OR} = 0.96, 95\% \text{ CI} = (0.61–2.99), P = 0.942 \) and patients on statins had a more normal computed tomography (CT) scan result \( \text{OR} = 0.41, 95\% \text{ CI} = (0.07–2.33), P = 0.312 \).

**Conclusions:** Although we could not demonstrate a significant association between statin use and a reduction in mortality in patients with COVID-19, we do feel that our results are promising and of clinical relevance and warrant the need for prospective randomized controlled trials and extensive retrospective studies to validate the potential beneficial effects of statin treatment on clinical symptoms and mortality rates associated with COVID-19.

**Background**

The novel coronavirus, SARS-CoV-2, causing coronavirus disease 2019 (COVID-19) is a major health threat that was declared a global pandemic by the World Health Organization (WHO) in March 2020 [1–3]. Since the outbreak in December 2019, many people have suffered from a severe acute respiratory infection that causes respiratory failure, the need for intubation, and prolonged mechanical ventilation [4]. Currently, the management of COVID-19 remains mostly supportive and depends on the severity of the disease, ranging from no support in asymptomatic patients to intubation and mechanical ventilation to manage acute respiratory distress syndrome (ARDS) in severe cases [5]. During the early stages of the pandemic, it was theorized that respiratory failure in COVID-19 may differ from typical ARDS [6]. These differences include the presence of good lung compliance, lack of pulmonary vasoconstriction, significant shunting and poor oxygenation, and concomitant features of thrombotic microangiopathy with endothelial dysfunction [7–9].
Apart from respiratory symptoms, most patients with SARS-CoV-2 infection have an increased risk of cardiovascular complications and thromboembolism, causing cerebrovascular events, deep vein thrombosis, or pulmonary embolism, that further complicates the post-infection course. Patients suffering from COVID-19 frequently present with multi-morbidity, meaning co-existence of multiple co-morbidities, including hypertension, cardiovascular disease, and diabetes. A retrospective analysis of 72,314 COVID-19 cases from China showed that patients with cardiovascular diseases exhibited significantly higher mortality (10.5% vs. 2.3%) [10]. The use of statins has been associated with a marked reduction in the risk of death from cardiovascular disease in the general population. Therefore, it has been proposed that statins through their pleiotropic modes of action, which include improvement of the endothelial function, and anti-inflammatory and antithrombotic effects [11–13], may therapeutically benefit COVID-19 patients. A recent retrospective investigation on 13,981 patients with COVID-19 (Hubei Province, China), of which 1,219 patients received statins, revealed that statin use was associated with reduced mortality [14].

Statins are conventionally used as cholesterol-lowering drugs, via inhibition of the mevalonate pathway, for the first-line therapeutic prevention of atherosclerotic cardiovascular diseases [15]. The discovery of their pleiotropic effects, independent of the cholesterol pathway, further attracted attention to this class of drugs [16]. The decreased mortality rate from cardiovascular diseases following statin consumption was attributed to both the lipid-lowering effect and enhancement of the vascular endothelial function [17–19]. The latter statin-effect has also been observed in other patient populations, including diabetics [20, 21] and women with polycystic ovary syndrome [22]. Various mechanisms have been reported for the statin-mediated improvement of endothelial function, e.g. reducing remnant lipoproteins [23], modulating the high mobility group box 1/toll-like receptor 4(HMGB1/TLR4) pathway [24], inhibiting miR-133a expression [25], inducing nitric oxide release [26], affecting Kruppel-like factor 2 signaling [27], and decreasing the level of acute-phase proteins (like C-reactive protein) [28]; of note, this last mechanism is also involved in the anti-inflammatory pleiotropic effects of statins [28, 29]. Due to their anti-inflammatory effects, statins showed beneficial effects in hypertensive patients with normal cholesterol levels [18, 19]. Several studies have identified the activation of autophagy as one of the primary molecular mechanisms underpinning the anti-inflammatory effects of statins [30–32].

In the current retrospective study, we investigated whether statin use is associated with an improved survival and clinical outcome in COVID-19 patients who were hospitalized in the Ali Asghar Hospital, Iran.

**Methods**

**Patient recruitment**

This was a retrospective study on a population of COVID-19 patients (ethics approval: IR.SUMS.REC.1399.151, Shiraz University of Medical Sciences) treated in a single tertiary hospital in Shiraz, Iran (ALIASGHAR Hospital), between March 1st and May 30th, 2020. We specifically focused on those patients who were discharged or had died by the end of May 2020 (Fig. 1). Hospitalized patients with the following inclusion criteria were included: COVID-19 pneumonia confirmed as per WHO criteria,
including a positive SARS-CoV-2 polymerase chain reaction (PCR) test of respiratory (nasopharynx, oropharynx) specimens, and evidenced by chest X-ray or chest computed tomography (CT) scan. The CT images were reviewed by an expert radiologist who was blind to the clinical information. Each CT scan was scrutinized for the presence of important radiologic features, including ground-glass opacity (GGO), consolidation, pleural effusion, septal thickening, and lymphadenopathy. The Radiological Society of North America Expert Consensus guidelines were implemented for the diagnosis of positive cases [33]. The peripheral bilateral GGOs, GGOs of rounded morphology, reverse halo sign, and other indications of organizing pneumonia were regarded as typical for the COVID-19 pneumonia. A radiologic severity score was applied in case of abnormal chest CT findings. Patients were also required to meet the following oxygenation inclusion criteria: SPO₂ ≤ 93% or PaO₂/FiO₂ < 300 mmHg < 300 mmHg. The exclusion criteria were: HIV, hepatitis B or C, influenza virus, or active tuberculosis infection; suspected active bacterial, fungal, or any other infections besides COVID-19; age < 19 and > 85 years old. In addition, patients with autoimmune or neoplastic diseases were excluded as they were using immune-modulators and/or anti-inflammatory medications or participated in drug clinical trials.

A total number of four hundred and fifty-nine (459) patients were initially considered eligible for inclusion. Of these patients, 34 were excluded in the primary screening because they did not meet the age criteria (Fig. 1). During the first phase of our investigation, 48 patients were transferred to other hospitals and excluded from the study because of the inability to follow-up. An additional 277 patients were excluded because important aspects of their medical records were missing (Fig. 1). Ultimately, a total of 150 laboratory-confirmed COVID-19 patients were included in this study, of which 75 had a history of statin therapy and were still using statin when they were hospitalized. Patients who used statins were matched with those that did not according to specific confounders, such as duration of the disease, COVID-19 medication, stage of the disease, history of the underlying disease, and age. Demographic, clinical treatment, and laboratory data (including serial samples for viral RNA detection) were extracted from the electronic medical records. All data were checked by the physicians and a researcher adjudicating any differences in the interpretation between the primary radiologist reviewers. After data collection, univariable logistic regression was performed to screen for predictors, after which multivariable logistic regression was conducted to evaluate the effects of statin therapy and other predictors on patient recovery.

**Statistical analysis**

Cox proportional-hazards regression models were used to estimate the association between statin use and risk of death. The proportional hazard (PH) assumption was checked for all the predictors with the Schoenfeld residuals analysis test [34] before model building. The PH assumption is very important to Cox regression; it means that the ratio of the hazards for any two individuals is constant over time. For example, if gender is one of the predictors in the Cox model, and the hazard of death for men is twice as high as for women, this must be constant over time. It dictates that time varying predictors cannot enter to the PH Cox model [34].
First, the univariate Cox regression was conducted for each predictor. Variables that had a significant association with the hazard of death in this analysis were subsequently entered into the multivariate Cox regression.

For adjusting the effect of confounders and estimating the pure association between statin consumption and time until death, we used four strategies: multivariate Cox regression, Weighted PH Cox, PH Cox after propensity score matching, and PH Cox adjusted with propensity score. In our study, individual matching was very difficult or even impossible because protecting the patient's life is a priority and all physicians want to prevent their patients from dying; therefore, they often prescribe several antibiotics and antivirals simultaneously. Consequently, there are several confounders, such as drugs and clinical, laboratory and CT characteristics.

A confounder is a variable that has an association with the exposure and the outcome simultaneously. In the statistical analysis of observational data, there is no randomization for the participants in the treatment groups. Therefore, the participant populations are not homogeneous based on the characteristic and clinical variables. For example, in our study, the patients in the statin and non-statin groups did not consume the exact same amount or type of antivirals, antibiotics and/or other drugs. There are many drug-related, laboratory and characteristic variables that are not similar between these groups; these heterogeneous variables lead to the bias estimation of the statin effect.

We used propensity score methods to reduce the effects of confounding factors. The propensity score analysis is a statistical technique that attempts to estimate the pure effect of treatment and removes or reduces the effect of other confounding variables. By using this method, the effects of all confounding variables are summarized into a score (the propensity score). The individual propensities were estimated with the use of a multivariable logistic regression model that included all confounding covariates. The statin use was the outcome in this multivariate logistic regression.

We performed three adjustment procedures with the propensity score. First, the individual propensity scores were inversed to calculate the inverse propensity score weights [35]. The weighted Cox regression model was conducted with these weights (Weighted PH Cox with inverse propensity score as weight). Second, since each individual has a propensity score, subjects from the two groups (statin vs no statin) could be matched based on their propensity scores [36]. In the propensity score matching analysis, the nearest-neighbor method was applied to create the best matches (PH Cox after propensity score matching). In the third propensity score adjustment procedure, the propensity score entered multivariate Cox regression as an additional covariate (PH Cox adjusted with propensity score). For the secondary analysis, we used logistic regression and the outcome was changed to CT result and mechanical ventilation. Multiple imputations were used to handle the missing data [37]. All statistical analyses were performed using R software, version 4.02 (R Project for Statistical Computing).

**Results**
For the 150 recruited participants with COVID-19 who met the inclusion criteria, the mean duration of hospitalization was 6.84 ± 4.35 days. The majority of patients was retired (29.7%) and majority of patients was retired and/or stayed occupied doing housework (31.8%). The mean age and BMI were 54.69 ± 4.35 years and 26.27 ± 3.68, respectively. Follow-up with these patients started at their admission and continued for 27 days. Over this period, 19 patients died from COVID19, whereas the other 131 patients survived and were discharged from the hospital. Three different types of statin were used among the 75 patients who used statins (atrovastatin (94.7%), rosuvastatin (2.7%), and simvastatin (2.7%) in the statin group, 22% and 14% had been using statins for 1–5 years and over 5 years, respectively, before hospital admission and the rest was using statin less than one year. The mean time of statin use was 7.37 ± 4.84 (SD) days during hospitalization.

Patients that used statins were older (65.61 vs. 58.77 years of age, \( P < 0.001 \)) and had a higher prevalence of comorbidities, including hypertension (48% vs. 10.7%, \( P < 0.001 \)), type 2 diabetes (33.3% vs. 9.3%, \( P < 0.001 \)), cardiovascular disease (2.7% vs. 0%, \( P < 0.001 \)), cerebrovascular diseases (10.7% vs. 1.3%, \( P < 0.001 \)), and chronic kidney diseases (25% vs. 8%, \( P < 0.001 \)), than those without statin therapy. On average, the statin group exhibited significantly increased leukocytes polymorphonuclear (LPMN) percentages (4.99 ± 2.55 vs. 4.94 ± 3.04) and lymphocyte counts (1.32 ± 0.84 vs. 1.79 ± 0.86) as compared to the non-statin group (\( P = 0.01 \)) (Table 1).
The baseline characteristics of the patients based on statin use are shown in Table 1, both in the unmatched and propensity score-matched samples. Before matching individuals in two groups (statin vs non-statin) based on the propensity score, some variables showed different distribution, but after matching, the majority showed similar distribution in both groups. In the unmatched samples, statin exposure differed according to age, addiction status, hypertension, diabetes, cardiovascular disease, chronic kidney disease, dyspnea, oxygen saturation (SpO\textsubscript{2}), LPMN percent count, lymphocyte count, prothrombin time, linezolid treatment, and mechanical ventilation (at least \(P<0.05\) for all).
The distribution of the estimated propensity scores among statin and no statin patients is shown in Fig. 2. As can clearly be observed, the histogram and density distribution of the estimated propensity scores were more balanced after adjustment. This shows that the two groups became more similar when considering mutual confounders that may affect the association between the main exposure variable (statins) and survival time. The C-statistic of the propensity score model was 0.75.

Figure 3 shows the Kaplan–Meier curve of the statin and non-statin groups. This plot suggested that before any adjustment (naive data) the statin group had a lower survival compared to the non-statin group; however, this difference was not statistically significant. ($P = 0.16$). The proportional hazard (PH) assumption was checked and approved for all the characteristic variables before conducting PH Cox model analyses (not shown). The crude and adjusted hazard ratios (HRs) for the association of characteristic variables on survival time are shown in Table 2. In the crude, unadjusted analysis, patients on statins seemed more likely to have a death event but this did not reach significance [$HR = 2.21$, 95% CI=$(0.71,6.90)$, $P = 0.174$]. The variables that showed a significant association in the univariate model (crude) were entered into the multivariate Cox regression model for adjustment purposes. In the multivariate Cox model, only mechanical ventilation had a significant effect on survival. Interestingly, the adjusted HR in the multivariate model that included mechanical ventilation was associated with an apparent lower risk of mortality in COVID19 patients on statins compared to non-statin users [$HR = 0.92$, 95% CI=$(0.21,4.16)$, $P = 0.918$]; although a promising observation, this association was not statistically significant. Figure 4 clarifies and highlights the difference between crude and propensity score-adjusted Cox regression plots for patient survival in the statin and non-statin groups. The results of five distinct Cox models with different adjustments are outlined in Table 3. No association was found between statin use and reduced mortality survival in the Cox analysis with inverse propensity score weighting (weighted Cox regression) [$HR = 0.94; 95\% CI= (0.22, 4.17)\), $P = 0.923$]. Based on a Cox model after propensity score matching, the HR for the statin group appeared to be associated with a lower risk of mortality [$HR = 0.85$, 95% CI=$(0.02,3.93)$, $P = 0.762$]. Similarly, additional propensity score analysis results (Cox regression with propensity score adjustment, model 5) also revealed that statin use was potentially associated with a decreased hazard of death [(HR = 0.76; 95% CI (0.16, 3.72), $P = 0.735$)]. Although these associations did not reach statistical significance, they do indicate that statin use might increase survival of COVID19 patients and that future prospective clinical trials and extensive retrospective studies are warranted to validate the potential therapeutic potential of statins in the amelioration of clinical symptoms and mortality rate associated with COVID19.
| Parameters                              | Crude          | Adjusted         |
|----------------------------------------|----------------|------------------|
| **Variables**                          | HR  | 95% CI for HR | P-value | HR  | 95% CI for HR | P-value |
| Age                                    | 1.02 | 0.97-1.05      | 0.294    | -   | -             | -       |
| BMI                                    | 1.05 | 0.82-1.39      | 0.503    | -   | -             | -       |
| Gender (men vs. women)                 | 1.16 | 0.45-3.01      | 0.760    | -   | -             | -       |
| Smoking vs. none                       | 0.83 | 0.26-2.67      | 0.751    | -   | -             | -       |
| Addiction vs. none                     | 1.63 | 0.45-5.95      | 0.482    | -   | -             | -       |
| **Triage vital signs**                 |     |                |          |     |                |         |
| Heart rate, beats per min             | 0.98 | 0.95-1.02      | 0.066    | -   | -             | -       |
| Respiratory rate, breaths per min     | 1.05 | 0.97-1.14      | 0.263    | -   | -             | -       |
| Systolic blood pressure (mm Hg)       | 0.66 | 0.60-0.99      | 0.806    | 1.01| 0.48-1.95     | 0.607   |
| Diastolic blood pressure (mm Hg)      | 0.93 | 0.88-0.95      | <0.005   | 0.95| 0.89-1.04     | 0.144   |
| Body temperature, Celsius degrees     | 1.06 | 0.70-1.81      | 0.781    | -   | -             | -       |
| Oxygen saturation (SpO2)              | 0.89 | 0.84-0.95      | <0.005   | 0.97| 0.86-1.10     | 0.637   |
| **Signs and symptoms**                |     |                |          |     |                |         |
| Chest pain vs. none                   | 0.51 | 0.06-4.25      | 0.531    | -   | -             | -       |
| Dyspnea vs. none                      | 2.49 | 0.97-10.38     | 0.229    | -   | -             | -       |
| Cough vs. none                        | 0.48 | 0.19-1.27      | 0.142    | -   | -             | -       |
| Headache vs. none                     | 1.60 | 0.39-6.38      | 0.379    | -   | -             | -       |
| **Comorbidities**                     |     |                |          |     |                |         |
| Hypertension                          | 2.27 | 0.86-5.75      | 0.086    | -   | -             | -       |
| Diabetes                               | 1.55 | 0.59-4.01      | 0.369    | -   | -             | -       |
| Cardiovascular disease                | 2.38 | 0.93-6.06      | 0.070    | -   | -             | -       |
| Respiratory disease                   | 1.19 | 0.54-4.15      | 0.787    | -   | -             | -       |
| Chronic kidney disease                | 4.20 | 1.65-10.67     | 0.005    | 2.21| 0.49-9.89     | 0.102   |
| **Laboratory measures**               |     |                |          |     |                |         |
| L/GM ratio percent                    | 1.04 | 1.05-1.06      | <0.005   | 1.04| 0.97-1.13     | 0.162   |
| Lymphocyte count                      | 0.88 | 0.81-0.95      | 0.001    | 1.04| 0.95-1.13     | 0.046   |
| Prothrombin time (PT)                 | 0.99 | 0.89-1.01      | 0.755    | -   | -             | -       |
| Internatinal Normalized Ratio (INR)   | 1.87 | 1.21-2.88      | 0.006    | 1.43| 0.58-3.35     | 0.441   |
| Creatine protein (CRI, mg/dL)         | 0.59 | 0.57-1.02      | 0.995    | -   | -             | -       |
| Serum Creatinine                      | 1.11 | 1.01-1.22      | 0.035    | 1.08| 0.88-1.35     | 0.461   |
| Hematocrit                            | 0.85 | 0.78-0.93      | 0.001    | 0.91| 0.79-1.04     | 0.774   |
| **Antibiotics therapy**               |     |                |          |     |                |         |
| Vancomycin vs. none                   | 1.10 | 0.46-3.35      | 0.901    | -   | -             | -       |
| Linezolid vs. none                    | 0.81 | 0.31-2.17      | 0.679    | -   | -             | -       |
| Ceftriaxone vs. none                  | 0.81 | 0.32-2.07      | 0.662    | -   | -             | -       |
| Azithromycin vs. none                 | 0.32 | 0.05-1.65      | 0.137    | -   | -             | -       |
| **Antifungal therapy**                |     |                |          |     |                |         |
| Itraconazole vs. none                 | 1.04 | 0.10-10.62     | 0.949    | -   | -             | -       |
| Lopinavir/Ritonavir vs. none          | 1.33 | 0.51-3.48      | 0.562    | -   | -             | -       |
| **Other therapy**                     |     |                |          |     |                |         |
| Glucocorticoids vs. none              | 3.17 | 1.16-8.66      | 0.085    | 0.67| 0.12-3.82     | 0.649   |
| ARB vs. none                          | 2.49 | 0.86-7.01      | 0.082    | -   | -             | -       |
| Statin vs. none                       | 2.11 | 0.71-6.30      | 0.174    | 0.92| 0.21-4.16     | 0.918   |
| Salibutamol vs. none                  | 0.52 | 0.18-1.62      | 0.226    | -   | -             | -       |
| Steroid vs. none                      | 0.35 | 0.09-1.16      | 0.167    | -   | -             | -       |
| **Respiratory support**               |     |                |          |     |                |         |
| Mechanical ventilation vs. none       | 11.01| 2.48-10.85     | 0.002    | 6.27| 1.03-31.27    | 0.047   |

HR: Hazard ratio; CI: confidence interval; BMI: body mass index; ARB: angiotensin receptor blocker

P-value less than 0.05 was considered significant.
As a secondary outcome, we used logistic regression to analyze the association of statin use with the incidence of invasive mechanical ventilation and abnormal CT results in COVID-19 patients. After adjusting with the propensity score, statin consumption was associated with a lower chance of being subjected to mechanical ventilation \([\text{OR} = 0.96, 95\% \; \text{CI} = (0.61-2.99), P = 0.942]\). In addition, patients in the statin group had lower chance of presenting with abnormal CT results \([\text{OR} = 0.41, 95\% \; \text{CI} = (0.07-2.33), P = 0.312]\) (Table 4).

Table 3. The effect of statin use on COVID-19 patient survival as assessed by the crude, multivariable and propensity score analysis

| Cox models                  | Model | HR   | 95% C.I for HR | P-value |
|-----------------------------|-------|------|----------------|---------|
| Crude                       | 1     | 2.21 | 0.71-6.90      | 0.174   |
| Multivariate Cox            | 2     | 0.92 | 0.21-4.16      | 0.918   |
| Weighted PH Cox (IPS as weight) | 3     | 0.94 | 0.22-4.17      | 0.923   |
| PH Cox after PS Matching    | 4     | 0.85 | 0.02-3.93      | 0.762   |
| PH Cox adjusted with PS     | 5     | 0.76 | 0.16-3.72      | 0.735   |

HR: hazard ratio; CI: confidence interval; PH: proportional hazard; PS: propensity score; IPS: inverse propensity score.

Table 4. The results of the crude and propensity score adjusted logistic regression for the secondary outcome

| Logistic regression models   | Crude          | Adjusted with PS |
|------------------------------|----------------|------------------|
|                              | OR  | 95% C.I for OR | P-value | OR  | 95% C.I for OR | P-value |
| **Secondary outcome**        |     |                |         |     |                |         |
| CT result (abnormal vs. normal) | 1.77 | 0.61-5.14      | 0.295   | 0.41 | 0.07-2.33      | 0.312   |
| Mechanical ventilation vs. none | 2.46 | 1.19-5.05      | **0.014** | 0.96 | 0.61-2.49      | 0.942   |

OR: odds ratio; CI: confidence interval; PS: propensity score.

Discussion

The results on statin use and its potential benefits for COVID-19 patients are controversial. In a recent meta-analysis, it was reported that “statin use did not improve in-hospital outcomes of COVID-19 infections” [38]; this analysis included 9 studies with a total of 3,449 patients. The results showed that statin use did not improve the outcome severity \([\text{OR} = 1.64, 95\% \; \text{CI} = (0.51-5.23), P = 0.41, I^2 = 93\%]\, random-effect modelling) or the mortality rate from COVID-19 infection \([\text{OR} 0.78, 95\% \; \text{CI} = (0.50-1.21), P = 0.26, I^2 = 0\%]\, fixed-effect modelling) [38]. This result might be due to their statistical analysis method. In an investigation on the use of statins in chronic renal disease patients with COVID-19, it was shown that statins reduced “the risk of neutrophilia \([\text{OR}-0.10, 95\% \; \text{CI} = (0.01-0.69)]\)” but did not affect the mortality in these patients [39]. Conversely, a relatively large retrospective study on 13,981 patients with COVID-19 (Hubei Province, China) revealed that statin use decreased all-cause mortality from 9.4–5.2% (a total of 1,219 patients received statins) [14]. In a recent investigation it has been also showed that statin use
decreased the in hospital mortality in COVID-19 patients with diabetes [40]. It has also been reported that using statin during hospitalization decrease the chance of ICU admission when compared to non-statin users [41]. It has been also showed that using statin decreased the risk of invasive mechanical ventilation in COVID-19 patients [42].

Based on our overall results, we feel that there is an indication that the use of statins may be linked to a lower risk of COVID19 mortality, even though this association did not reach statistical significance [HR = 0.924, 95% CI=(0.205, 4.157), P = 0.918]. In addition, statins significantly reduced the need for mechanical ventilation and improved lung CT in COVID-19 patients. Although promising and clinically relevant, our observed associations between statin use and survival of COVID19 patients were not statistically significant, likely due to impaired power of our analysis as a result of the many patients that had to be excluded, and need to be validated in prospective clinical trials and extensive retrospective studies. Considering the many documented pleotropic effects of statins and the results presented here, we anticipate positive effects of statin use on the clinical outcomes of COVID-19 patients.

Pleiotropic effects of statins have been reported in several malignancies, especially respiratory infections [43, 44], acute lung injury [45], pulmonary hypertension [46], community-acquired pneumonia, chronic obstructive pulmonary disease [47], and interstitial lung disease [48]. Statins have shown various beneficial anti-inflammatory and immunomodulatory properties by affecting intracellular signaling pathways [49, 50] that are independent of their lipid-lowering ability [51]. Furthermore, antiviral effects against the influenza virus have been demonstrated in several in vitro and in vivo studies [52–55]. Statins modulate the antiviral response in human bronchial and epithelial cells, which constitute the first line of defense against invading pathogens [56], and significantly reduce the production of pro-inflammatory cytokines, such as TNF-α and IL-6, in Crandell feline kidney cells infected with H1N1 [57]. In primary normal human bronchial epithelial cells (NHBE) and human type II pneumocyte cell line A549, simvastatin attenuated viral dsRNA-induced AKT phosphorylation, STAT3 activation, and subsequent production of RANTES [58]. In another study, simvastatin was shown to reduce the replication of H1N1 by blocking RhoA membrane localization, actin filaments condensation, Rab protein expression during endocytosis, and LC3-II protein localization [53].

The effect of statins on the Coronaviridae family is still under-studied. Earlier in 2015, it was proposed that a high dose of atorvastatin may work against MERS-CoV infections by decreasing inflammatory cytokines [59]. However, statins may not be very effective in late-stage patients but timely use of statins could be vital for the survival of MERS-CoV infected patients [59]. Since some investigations had confirmed the association of statin therapy with a reduction in cardiovascular outcomes and mortality in patients infected with influenza, it was also suggested that COVID19 patients, with severe damage to lung tissue caused by a cytokine storm of inflammatory mediators, continue statin therapy for its potential clinical benefit [60]. An in silico docking study highlighted that statins might be efficient inhibitors of the SARS-CoV-2 main protease [61]. Moreover, selective statins (fluvastatin was more efficient than other statins) reduced SARS-CoV-2 cell entry and inhibited infection of human respiratory epithelial cells by either the low pathogenic (coronavirus 229E) or highly pathogenic (2019-nCoV)
coronavirus. It was contributed with mild attenuation of SARS-CoV-2 infection in vitro [62]. This study also showed that statin therapy did not cause any additional risk to these patients and that some statins may have a mild beneficial effect on COVID-19 outcome [62].

Autophagy is an important cellular mechanism against different types of stress, including viral infection [3, 63, 64]. SARS-CoV-2 infection likely changes autophagy flux in the infected cells and hijacks it for its replication [3]. The clinical effects of statins described to date have in part been attributed to their impact on the cellular autophagy pathway. Indeed, several studies have reported the involvement of the autophagy pathway as a mechanism for the protective effects of statins in the human lung [65, 66]. Using airway mesenchymal cells, we demonstrated the potential for statins to have beneficial effects in obstructive airways diseases by induction of autophagy via upregulation of p53 [67] as well as through their effects on other pathways, such as the unfolded protein response [68]. Using a mouse model of asthma, simvastatin was shown to ameliorate key asthmatic symptoms (airway remodeling and inflammation) in the lungs via autophagy augmentation [32]. Therefore, it is conceivable that statins may target SARS-CoV-2 infection in lung epithelial cells via the autophagy pathway.

Statins have shown modulatory effects on angiotensin-converting enzyme 2 (ACE2) expression. Qi and co-workers were the first to study the expression of ACE2 in cardio-myocytes of rats with cardiac hypertrophy and reported a decreased expression of both ACE2 mRNA and protein levels in response to 4 weeks of treatment with 5 mg/kg/day of atorvastatin [69]. Later, similar effects on aortic arteries in vascular balloon injured rats treated with the same doses of rosuvastatin for 2 to 4 weeks were reported [70]. However, other studies presented conflicting observations. In a cellular model of vascular smooth muscle cell hypertrophy, atorvastatin recovered the molecular changes induced by TNF-α and increased ACE2 mRNA expression [71]. Using a rabbit model of atherosclerosis, an association between atherosclerosis and a reduced level of ACE2 in both renal and cardiac tissue was established; ACE2 levels were replenished following 3 weeks of atorvastatin administration [72]. Since the significance of ACE2 expression in diabetes surfaced [73], scientists have focused on the potential role of statins in diabetes. Aguilar and colleagues showed that atorvastatin increased ACE2 mRNA in cardiomyocytes of diabetic cardiomyopathic rats, which was associated with a reduction in fibrosis and hypertrophy of the left ventricles [74]. These effects were attributed to the recovered ratio of ACE/ACE2 rather than an increased level of ACE2 [74]. Further studies in diabetic rats confirmed that statin administration increased ACE2 mRNA in cardiac tissue from insulin-controlled groups, although this was not accompanied by significant effects on cardiac fibrosis and reactive oxygen species generation [75, 76]. In our current report, 33% of COVID19 cases that used statins were diabetic. Although diabetes is among the comorbidity factors for COVID-19 mortality, none of the diabetic COVID19 patients on statins enrolled in our study died because of COVID-19 infection.

In addition to their anti-inflammatory actions, our recent investigation showed that statins inhibit tissue damage by reducing extracellular matrix synthesis in airway mesenchymal cells [77, 78]. Several studies have shown beneficial effects of statins in the treatment and recovery of patients with idiopathic pulmonary fibrosis and implied that statins improve lung function by acting on fibrosis mediators [79,
In addition, statins reduce mortality in these patients and those with interstitial lung disease [81]. Simvastatin reduces the connective tissue growth factor and transforming growth factor-beta (TGFβ) in lung fibroblasts through inhibition of Rho signaling [78, 82, 83]. Following a decrease in TGFβ, TGF-β1-induced fibronectin production by fibroblasts and epithelial-mesenchymal transition of respiratory epithelial cells are also reduced [77, 84]. Finally, simvastatin reduces the collagen deposition in alveolar cells of the lung and prevents the progression of pulmonary fibrosis [85].

**Conclusion**

Overall, we propose that statin use can potentially protect SARS-CoV-2-induced tissue damage and improve lung function in COVID-19 patients via different pleiotropic effects. These effects include targeting the SARS-CoV-2-induced inflammation and cytokine storm, inhibition of cellular trafficking via targeting autophagy pathway, mediating ACE2 expression, and decreasing extracellular matrix biosynthesis and scar formation in COVID-19 patients. The results of our current work may have some different outcomes than shown by the Zhang et al investigation in China [14], likely because of differences in the number (limitation of our current study) and genetic background of the patients involved. Although we could not demonstrate a significant association between statin use and a reduction in COVID19 mortality, our results are promising and clinically relevant and warrant the need for prospective randomized controlled trials and extensive retrospective studies in large and diverse patient populations to further evaluate the potential beneficial therapeutic effects of statin treatment on clinical symptoms and mortality rates associated with COVID-19. We believe that statins could represent a strong adjuvant/adjunct therapeutic strategy in addition to other (antiviral) therapies currently used against COVID-19.

**Declarations**

**Ethics approval and consent to participate:** This was a retrospective study on a population of COVID-19 patients. The ethics approval: IR.SUMS.REC.1399.151, Shiraz University of Medical Sciences. All participants consented for participation into the study.

**Consent for publication:** All authors gave consent for publication.

**Availability of data and materials:** All data of the manuscript will be provided upon request after the request being approved by ethic committee.

**Competing interests:** There is no competing interest in the study.

**Funding:** The project was funded by Shiraz University of Medical Sciences

**Author Contribution:** Payam Peymani and Tania Dehesh did the statistical analysis. Farnaz Aligolighasemabadi and Mohammadamin Sadeghdoust collected all raw data blindly. Katarzyna Kotfis provided feedback of clinical aspects of COVID-19 and helped for the writing the draft. Mazaher Ahmadi
and Taybeh Madrakian helped for providing oversight on the chemical structures and functions of statins. Parvaneh Mehrbod provided feedback on antiviral effects of statins and prepared the draft on this part. Sanaz Dastghaib and Ahmad Nasimian evaluated laboratory data of patients and helped preparing this part of data. Amir Ravandi provided feedback on heart and diabetes related complications of the patients. Biniam Kidane Naseer Ahmed and Pawan Sharma provided feedback on the lung complications of patients, Shahla Shojaei and Hagar Laboua helped on evaluation of pleiotropic effect of statins. Kamran Bagheri Lankarani and Nima Rezaei helped in cases related to COVID-19 and internal medicine. Pooneh Mokarram and Saeid Ghavami led the team, finalized the draft of manuscript and supervised the project. Andrzej Madej and Marek Los worked on the clinical data and provided feedback on final article.

**Acknowledgement:** The authors acknowledge Shiraz Medical University of Medical Science for financial support. The authors would like to thank Science Impact (Winnipeg, Canada) for (post)editing the manuscript.

**References**

1. Drozdal S, Rosik J, Lechowicz K, Machaj F, Kotfis K, Ghavami S, Los MJ: **FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.** *Drug Resist Updat* 2020, **53**:100719.

2. Sureda A, Alizadeh J, Nabavi SF, Berindan-Neagoe I, Cismaru CA, Jeandet P, Los MJ, Clementi E, Nabavi SM, Ghavami S: **Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management?** *Eur J Pharmacol* 2020, **882**:173288.

3. Shojaei S, Suresh M, Klionsky DJ, Laboua HI, Ghavami S: **Autophagy and SARS-CoV-2 infection: A possible smart targeting of the autophagy pathway.** *Virulence* 2020, **11**:805-810.

4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al: **Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.** *Lancet* 2020, **395**:497-506.

5. Organization WH: **Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (NCoV) Infection Is Suspected.** WHO; 2020.

6. Rello J, Storti E, Belliato M, Serrano R: **Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers.** *Eur Respir J* 2020, **55**.

7. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H: **Endothelial cell infection and endotheliitis in COVID-19.** *Lancet* 2020, **395**:1417-1418.

8. Gavriilaki E, Brodsky RA: **Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily.** *Br J Haematol* 2020, **189**:e227-e230.

9. Tang N, Li D, Wang X, Sun Z: **Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.** *J Thromb Haemost* 2020, **18**:844-847.
10. Wu Z, McGoogan JM: Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020.

11. Lee KCH, Sewa DW, Phua GC: Potential role of statins in COVID-19. Int J Infect Dis 2020, 96:615-617.

12. Subir R, Jagat JM, Kalyan KG: Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19). Diabetes Metab Syndr 2020, 14:1225-1229.

13. Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN: Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs 2020.

14. Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, Yuan Y, Lei F, Chen MM, Yang H, Bai L, et al: In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab 2020, 32:176-187 e174.

15. Adhyaru BB, Jacobson TA: Safety and efficacy of statin therapy. Nat Rev Cardiol 2018, 15:757-769.

16. Istvan ES, Deisenhofer J: Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001, 292:1160-1164.

17. Lim S, Sakuma I, Quon MJ, Koh KK: Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality. Int J Cardiol 2013, 167:1696-1702.

18. Schneider MP, Schmidt BM, John S, Schmieder RE: Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. J Hypertens 2011, 29:1757-1764.

19. Katsiki N, Mikhailidis DP, Banach M: Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. J Hypertens 2011, 29:2493-2494; author reply 2494.

20. Zhang L, Gong D, Li S, Zhou X: Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus. Atherosclerosis 2012, 223:78-85.

21. Adel A, Abdel-Salam Z, Nammas W: Low-dose statin therapy improves endothelial function in type 2 diabetic patients with normal serum total cholesterol: a randomized placebo-controlled study. J Clin Hypertens (Greenwich) 2010, 12:820-825.

22. Yang B, Sun ZJ, Chen B, Zhang J, Zhao H, Li CW, Cao YK, Cao F: Statin ameliorates endothelial dysfunction and insulin resistance in Tibet women with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci 2016, 20:1185-1191.

23. Nakamura T, Uematsu M, Yoshizaki T, Kobayashi T, Watanabe Y, Kugiyama K: Improvement of endothelial dysfunction is mediated through reduction of remnant lipoprotein after statin therapy in patients with coronary artery disease. J Cardiol 2020, 75:270-274.

24. Zhu Z, Fang Z: Statin protects endothelial cell against ischemia reperfusion injury through HMGB1/TLR4 pathway. Int J Cardiol 2016, 203:74.

25. Li P, Yin YL, Guo T, Sun XY, Ma H, Zhu ML, Zhao FR, Xu P, Chen Y, Wan GR, et al: Inhibition of Aberrant MicroRNA-133a Expression in Endothelial Cells by Statin Prevents Endothelial Dysfunction by
Targeting GTP Cyclohydrolase 1 in Vivo. *Circulation* 2016, 134:1752-1765.

26. Cerda A, Fajardo CM, Basso RG, Hirata MH, Hirata RD: Role of microRNAs 221/222 on statin induced nitric oxide release in human endothelial cells. *Arq Bras Cardiol* 2015, 104:195-201.

27. Ali F, Hamdulay SS, Kinderlerer AR, Boyle JJ, Liddington EA, Yamaguchi T, Soares MP, Haskard DO, Randi AM, Mason JC: Statin-mediated cytoprotection of human vascular endothelial cells: a role for Kruppel-like factor 2-dependent induction of heme oxygenase-1. *J Thromb Haemost* 2007, 5:2537-2546.

28. Momin A, Melikian N, Wheatcroft SB, Grieve D, John LC, El Gamel A, Marrinan MT, Desai JB, Driver C, Sherwood R, et al: The association between saphenous vein endothelial function, systemic inflammation, and statin therapy in patients undergoing coronary artery bypass surgery. *J Thorac Cardiovasc Surg* 2007, 134:335-341.

29. Ahmadi M, Amiri S, Pecic S, Machaj F, Rosik J, Los MJ, Alizadeh J, Mahdian R, da Silva Rosa SC, Schaafsma D, et al: Pleiotropic effects of statins: A focus on cancer. *Biochim Biophys Acta Mol Basis Dis* 2020, 1866:165968.

30. Han F, Xiao QQ, Peng S, Che XY, Jiang LS, Shao Q, He B: Atorvastatin ameliorates LPS-induced inflammatory response by autophagy via AKT/mTOR signaling pathway. *J Cell Biochem* 2018, 119:1604-1615.

31. Peng S, Xu LW, Che XY, Xiao QQ, Pu J, Shao Q, He B: Atorvastatin Inhibits Inflammatory Response, Attenuates Lipid Deposition, and Improves the Stability of Vulnerable Atherosclerotic Plaques by Modulating Autophagy. *Front Pharmacol* 2018, 9:438.

32. Gu W, Cui R, Ding T, Li X, Peng J, Xu W, Han F, Guo X: Simvastatin alleviates airway inflammation and remodelling through up-regulation of autophagy in mouse models of asthma. *Respirology* 2017, 22:533-541.

33. Simpson S, Kay FU, Abbara S, Bhalla S, Chung JH, Chung M, Henry TS, Kanne JP, Kligerman S, Ko JP, Litt H: Radiological Society of North America Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA. *Radiology: Cardiothoracic Imaging* 2020, 2:e200152.

34. Kleinbaum DG, Klein M: *Survival analysis*. Springer; 2010.

35. Robins JM, Hernan MA, Brumback B: Marginal structural models and causal inference in epidemiology. LWW; 2000.

36. Rosenbaum PR, Rubin DB: The central role of the propensity score in observational studies for causal effects. *Biometrika* 1983, 70:41-55.

37. Rubin DB: *Multiple imputation for nonresponse in surveys*. John Wiley & Sons; 2004.

38. Hariyanto TI, Kurniawan A: Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. *Diabetes Metab Syndr* 2020, 14:1613-1615.

39. Yang D, Xiao Y, Chen J, Chen Y, Luo P, Liu Q, Yang C, Xiong M, Zhang Y, Liu X, et al: COVID-19 & Chronic Renal Disease: Clinical characteristics & prognosis. *QJM* 2020.
40. Saeed O, Castagna F, Agalliu I, Xue X, Patel SR, Rochlani Y, Kataria R, Vukelic S, Sims DB, Alvarez C, et al: 
Statin Use and In-Hospital Mortality in Diabetics with COVID-19. J Am Heart Assoc 2020:e018475.
41. Tan WYT, Young BE, Lye DC, Chew DEK, Dalan R: Statin use is associated with lower disease severity in COVID-19 infection. Sci Rep 2020, 10:17458.
42. Song SL, Hays SB, Panton CE, Mylona EK, Kalligeros M, Shehadeh F, Mylonakis E: Statin Use Is Associated with Decreased Risk of Invasive Mechanical Ventilation in COVID-19 Patients: A Preliminary Study. Pathogens 2020, 9.
43. Van De Garde EM, Hak E, Souverein PC, Hoes AW, van den Bosch JM, Leufkens HG: Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006, 61:957-961.
44. Khurana VBH, Caldito G, Owens MW: Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 2007, 131:1282-1288.
45. Jacobson JR, Barnard JW, Grigoryev DN, Ma SF, Tuder RM, Garcia JGN: Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. American Journal of Physiology - Lung Cellular and Molecular Physiology 2005, 288:L1026-L1032.
46. Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH: Reduction in blood pressure with statins: Results from the UCSD statin study, a randomized trial. Archives of Internal Medicine 2008, 168:721-727.
47. Furberg CD: Natural statins and stroke risk. Circulation 1999, 99:185-188.
48. Feldman C: The role of statins in respiratory diseases. Clinical Pulmonary Medicine 2009, 16:95-100.
49. Liao JK, Laufs U: Pleiotropic effects of statins. Annual Review of Pharmacology and Toxicology 2005, 45:89-118.
50. Terblanche M, Smith TS, Adhikari NKJ: Statins, bugs and prophylaxis: intriguing possibilities. Critical Care 2006, 10:168.
51. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG: Statins and sepsis: multiple modifications at multiple levels. The Lancet Infectious Diseases 2007, 7:358-368.
52. Mehrbod P, Ideris A, Omar ARB, Hair-Bejo M: Evaluation of antiviral effect of atorvastatin on H1N1 infection in MDCK cells. African Journal of Microbiology Research 2012, 6:5715-5719.
53. Mehrbod P, Hair-Bejo M, Tengku Ibrahim TA, Omar AR, Eizwaldaty M, Ajdari Z, Ideris A: Simvastatin modulates cellular components in influenza A virus-infected cells. Int J Mol Med 2014, 34:61-73.
54. Kwong JC, Li P, Redelmeier DA: Influenza morbidity and mortality in elderly patients receiving statins: a cohort study. PLoS One 2009, 4:e8087.
55. Vandermeer ML, Thomas AR, Kamimoto L, Reingold A, Gershman K, Meek J, Farley MM, Ryan P, Lynfield R, Baumbach J, et al: Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2012, 205:13-19.
56. Inoue I, Goto SI, Mizotani K, Awata T, Mastunaga T, Kawai S, Nakajima T, Hokari S, Komoda T, Katayama S: Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of
mRNA levels for interleukin-1, interleukin-6, cyclooxygenase-2 and p22phox by regulation of peroxisome proliferator-activated receptor (PPAR) in primary endothelial cells. *Life Sciences* 2000, 67:863-876.

57. Mehrbod P, El Zowalaty M, Omar AR, Hair-Bejo M, Ideris A: *Statins reduce the expression of proinflammatory cytokines in influenza A virus infected CrFK cells.* *Acta Virologica* 2012, 56:353-355.

58. Lee CS, Yi EH, Lee JK, Won C, Lee YJ, Shin MK, Yang YM, Chung MH, Lee JW, Sung SH, Ye SK: *Simvastatin suppresses RANTES-mediated neutrophilia in polyinosinic-polycytidylic acid-induced pneumonia.* *Eur Respir J* 2013, 41:1147-1156.

59. Yuan S: *Statins may decrease the fatality rate of Middle East Respiratory Syndrome infection.* *mBio* 2015, 6:e01120-01115.

60. Virani SS: *Is there a role for statin therapy in acute viral infections?* *Cardiology Magazine* 2020, https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/09/is-there-a-role-for-statin-therapy-in-acute-viral-infections-covid-19.

61. Reiner Ž, Hatamipour M, Banach M, Pirro M, Al-Rasadi K, Jamialahmadi T, Radenkovic D, Montecucco F, Sahebkar A: *Statins and the COVID-19 main protease: in silico evidence on direct interaction.* *Archives of Medical Science* 2020, 16:490-496.

62. Moeller R, Zapatero-Belinchon FJ, Lasswitz L, Kirui J, Brogden G, Gunesch AP, Pietschmann T, Wichmann D, Kluge S, Gerold G: *Effect of statins on SARS-CoV-2 infection.* *medRxiv* 2020:2020.2007.2013.20152272.

63. Mehrbod P, Ande SR, Alizadeh J, Rahimizadeh S, Shariati A, Malek H, Hashemi M, Glover KKM, Sher AA, Coombs KM, Ghavami S: *The roles of apoptosis, autophagy and unfolded protein response in arbovirus, influenza virus, and HIV infections.* *Virulence* 2019, 10:376-413.

64. Yeganeh B, Ghavami S, Rahim MN, Klonisch T, Halayko AJ, Coombs KM: *Autophagy activation is required for influenza A virus-induced apoptosis and replication.* *Biochim Biophys Acta Mol Cell Res* 2018, 1865:364-378.

65. Zeki AA, Kenyon NJ, Goldkorn T: *Statin drugs, metabolic pathways, and asthma: a therapeutic opportunity needing further research.* *Drug Metab Lett* 2011, 5:40-44.

66. Thong L, MacSharry J, Murphy DM: *The Effects of Statin Therapy on the Human Airway.* *Drug Metab Lett* 2016, 10:75-82.

67. Ghavami S, Mutawe MM, Sharma P, Yeganeh B, McNeill KD, Klonisch T, Unruh H, Kashani HH, Schaafsma D, Los M, Halayko AJ: *Mevalonate cascade regulation of airway mesenchymal cell autophagy and apoptosis: a dual role for p53.* *PLoS One* 2011, 6:e16523.

68. Ghavami S, Sharma P, Yeganeh B, Ojo OO, Jha A, Mutawe MM, Kashani HH, Los MJ, Klonisch T, Unruh H, Halayko AJ: *Airway mesenchymal cell death by mevalonate cascade inhibition: integration of autophagy, unfolded protein response and apoptosis focusing on Bcl2 family proteins.* *Biochim Biophys Acta* 2014, 1843:1259-1271.

69. Qin XT, Jia CW, Pan M, Shen AG, Jing HM: *[Effect of atorvastatin on ACE2 expression in pressure overload induced cardiac hypertrophy in rats].* *Zhong Nan Da Xue Xue Bao Yi Xue Ban* 2008, 33:438-
442.

70. Li YH, Wang QX, Zhou JW, Chu XM, Man YL, Liu P, Ren BB, Sun TR, An Y: Effects of rosuvastatin on expression of angiotensin-converting enzyme 2 after vascular balloon injury in rats. J Geriatr Cardiol 2013, 10:151-158.

71. Suski M, Gębska A, Olszanecki R, Stachowicz A, Uracz D, Madej J, Korbut R: Influence of atorvastatin on angiotensin I metabolism in resting and TNF-α-activated rat vascular smooth muscle cells. J Renin Angiotensin Aldosterone Syst 2014, 15:378-383.

72. Tikoo K, Patel G, Kumar S, Karpe PA, Sanghavi M, Malek V, Srinivasan K: Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications. Biochem Pharmacol 2015, 93:343-351.

73. Warner FJ, Guy JL, Lambert DW, Hooper NM, Turner AJ: Angiotensin converting enzyme-2 (ACE2) and its possible roles in hypertension, diabetes and cardiac function. 2003, 10:377-385.

74. Aguilar C, Ventura F, Rodríguez-Delfín L: [Atorvastatin induced increase in homologous angiotensin I converting enzyme (ACE2) mRNA is associated to decreased fibrosis and decreased left ventricular hypertrophy in a rat model of diabetic cardiomyopathy]. Rev Peru Med Exp Salud Publica 2011, 28:264-272.

75. Shin YH, Min JJ, Lee JH, Kim EH, Kim GE, Kim MH, Lee JJ, Ahn HJ: The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts. Heart Vessels 2017, 32:618-627.

76. Min JJ, Shin BS, Lee JH, Jeon Y, Ryu DK, Kim S, Shin YH: Effects of Pravastatin on Type 1 Diabetic Rat Heart with or without Blood Glycemic Control. J Diabetes Res 2018, 2018:1067853.

77. Schaafsma D, McNeill KD, Mutawe MM, Ghavami S, Unruh H, Jacques E, Laviolette M, Chakir J, Halayko AJ: Simvastatin inhibits TGFβ1-induced fibronectin in human airway fibroblasts. Respiratory research 2011, 12:113.

78. Schaafsma D, Dueck G, Ghavami S, Kroeker A, Mutawe MM, Hauff K, Xu FY, McNeill KD, Unruh H, Hatch GM: The mevalonate cascade as a target to suppress extracellular matrix synthesis by human airway smooth muscle. American journal of respiratory cell and molecular biology 2011, 44:394-403.

79. Kreuter M, Costabel U, Richeldi L, Cottin V, Wijsenbeek M, Bonella F, Bendstrup E, Maher TM, Wachtlin D, Stowasser S: Statin therapy and outcomes in trials of nintedanib in idiopathic pulmonary fibrosis. Respiration 2018, 95:317-326.

80. Kreuter M, Bonella F, Maher TM, Costabel U, Spagnolo P, Weycker D, Kirchgaessler K-U, Kolb M: Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax 2017, 72:148-153.

81. Vedel-Krogh S, Nielsen SF, Nordestgaard BG: Statin use is associated with reduced mortality in patients with interstitial lung disease. PloS one 2015, 10:e0140571.

82. Yeganeh B, Wiechec E, Ande SR, Sharma P, Moghadam AR, Post M, Freed DH, Hashemi M, Shojaei S, Zeki AA: Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Pharmacology & therapeutics 2014, 143:87-110.
83. Watts K, Cottrell E, Hoban P, Spiteri M: RhoA signaling modulates cyclin D1 expression in human lung fibroblasts; implications for idiopathic pulmonary fibrosis. Respiratory Research 2006, 7:88.

84. Yang T, Chen M, Sun T: Simvastatin attenuates TGF-β1-induced epithelial-mesenchymal transition in human alveolar epithelial cells. Cellular Physiology and Biochemistry 2013, 31:863-874.

85. Bagnato G, Bitto A, Pizzino G, Irrera N, Sangari D, Cinquegrani M, Roberts WN, Matucci Cerinic M, Squadrito F, Altavilla D: Simvastatin attenuates the development of pulmonary and cutaneous fibrosis in a murine model of systemic sclerosis. Rheumatology 2013, 52:1377-1386.

Figures

Flow-chart of patient enrolment and summary of the inclusion and exclusion criteria.
Figure 2

Histogram and density distribution plots of the estimated propensity scores, before and after propensity score adjustment in statin and non-statin patient groups. The left side of the figure (unadjusted) shows that the non-statin group had more density on the right side of the plot versus the statin group that had more density on the left side of the plot. After adjustment (right side of the figure), both groups displayed similar densities. The results show that the two groups became more similar when considering mutual confounders that may affect the association between the main exposure variable (statins) and survival time. The C-statistic of the propensity score model was 0.75.
Figure 3

Kaplan-Meier plot comparing the survival time (in days) between the statin and non-statin groups. This plot suggests that before any adjustment (naive data) mortality was lower in the statin than the non-statin group. However, the P-value of the log-rank test (P=0.16) did not indicate any significant difference.
Figure 4

Crude survival and propensity score-adjusted Cox plots comparing the survival time (in days) between the statin and non-statin groups. The plots highlights the difference between crude and propensity score-adjusted survival Cox regression plots for the statin and non-statin patient populations. These plots suggest that before adjustment (left plot), the statin group displayed a lower survival time, whereas after adjustment (right plot), statin users showed a higher survival probability; however, neither of these differences was significant.